Lisata Therapeutics Inc (LTS:0HS8)
$ 3.255 0 (0%) Market Cap: 28.95 Mil Enterprise Value: -14.23 Mil PE Ratio: 0 PB Ratio: 0.67 GF Score: 37/100

Q1 2020 Caladrius Biosciences Inc Earnings Call Transcript

May 07, 2020 / 08:30PM GMT
Release Date Price: $28.2
Operator

Hello, and welcome to the Caladrius Biosciences First Quarter 2020 Financial Results and Business Update Conference Call. (Operator Instructions) As a reminder, this call is being recorded today, Thursday, May 7, 2020.

I will now turn the call over to John Menditto, Vice President of Investor Relations and Corporate Communications at Caladrius. Please go ahead, sir.

John D. Menditto
Caladrius Biosciences, Inc. - VP of IR & Corporate Communications

Good afternoon, and thank you all for participating in today's call.

Joining me today from our management team are Dr. David Mazzo, President and Chief Executive Officer; Dr. Douglas Losordo, Chief Medical Officer; and Joseph Talamo, Chief Financial Officer.

Earlier today, we issued a press release announcing our 2020 first quarter financial results. If you have not received this news release or if you would like to be added to the company's e-mail distribution list, please e-mail me at [email protected].

Before we begin, I will remind you that comments made by

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot